Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary Aspergillosis

Gerardo Quezada, Nadezhda V. Koshkina, Patrick Zweidler-McKay, Zichao Zhou, Dimitrios P. Kontoyiannis, Eugenie S. Kleinerman

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

We demonstrated that intranasal granulocyte-macrophage colony-stimulating factor given to immunosuppressed mice infected with pulmonary aspergillosis resulted in a sixfold reduction in the lung fungal burden compared to the result for saline-treated mice (P = 0.045). These data suggest that lung-targeted immunotherapy may be complementary to antifungal agents and may improve patient responses.

Original languageEnglish (US)
Pages (from-to)716-718
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume52
Issue number2
DOIs
StatePublished - Feb 2008

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary Aspergillosis'. Together they form a unique fingerprint.

Cite this